[Thromboembolic events at the time of highly active antiretroviral therapies against human immunodeficiency virus].
OBJECTIVE
Vein thrombosis risk and pulmonary embolism seem to be more important among human immunodeficiency virus (HIV) infected patients.


METHODS
We performed a retrospective study including 780 HIV positive patients followed-up between January 2000 and June 2005 at the University Hospital of Clermont-Ferrand.


RESULTS
Among the 780 HIV-infected patients, six cases of thromboembolic events were identified including, four with pulmonary embolism. All the patients were receiving lopinavir/ritonavir combination.


CONCLUSIONS
Although uncommon, pulmonary embolism occurs more frequently among HIV positive patients than in general population. Clinicians must remain aware about the possibility of the occurrence of a thromboembolic event especially during the first few months after introduction of the antiretroviral therapy.
Lyonne
L
L
Service maladies infectieuses et tropicales - Premier HO, CHU Gabriel-Montpied, 58, rue Montalembert, 63003 Clermont-Ferrand cedex 1, France.
Magimel
C
C
Cormerais
L
L
Trouillier
S
S
Bocquier
B
B
Zenut
M
M
Jacomet
C
C
Laurichesse
H
H
Beytout
J
J
Lesens
O
O
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data*; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D005602:France / Q000453:epidemiology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006679:HIV Seropositivity / Q000453:epidemiology; D006801:Humans; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000453:epidemiology*; D011744:Pyrimidinones / Q000627:therapeutic use; D012189:Retrospective Studies; D019438:Ritonavir / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000453:epidemiology*
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir